















Mergers & Acquisitions 


























Dissertation submitted in partial fulfillment of requirements for the degree of Master in 








A glance at the worldwide M&A activity of pharmaceutical companies tells us that 
consolidation within this sector has not been reached and won’t be soon. The trend of 
acquiring small biotech start-ups with promising research pipelines is essential for big 
pharmas to survive their highly competitive sector. Additionally, the global population is 
rapidly aging and hence, age-related diseases like Alzheimer Disease (AD) will increase and, 
with them, the need for treatments will rise. Therefore, big pharmaceutical companies need to 
strengthen their product pipelines with efficient, innovative market-disrupting solutions.  
For Roche, one of the world’s largest pharmaceuticals, the need to enhance their neuroscience 
product pipeline has recently increased, due to the failure in passing Phase III of its most 
promising AD drug in 2014. To “solve” this issue, this work provides a detailed evaluation of 
a potential M&A deal between Roche and the small German biotech Probiodrug, which, 
through an innovative approach, created a highly promising AD product, currently in Phase II. 
With successful approval of this product this deal will provide Roche with an increase in 
future sales and gives more potential for further research.  
This work argues that Roche should make an offer with a 41% premium over todays share 
price, which is equal to EUR 29,78 per share. The total deal value will be EUR 202 mm and 
paid 100% in cash. Considering the possible synergy creation of the acquisition, in 
negotiations the total offer price might range from 41% up to 120% over the current share 
price. 
